Stem cell therapy could be one of the complementary treatments to alleviate sufferings in Covid-19 patients
By AZALEA AZUAR
ACCORDING to a recent study and clinical trial in China, mesenchymal stem cell (MSC) therapy has been shown to alleviate pneumonia and acute respiratory syndrome (ARDS) symptoms through their immunomodulatory activities in Covid-19 patients.
Although more research studies and clinical trial results are needed to demonstrate the use of stem cells in providing relief to Covid-19 patients, the findings have been rather encouraging.
Patients treated with MSCs have somehow regained lung functions and have restored levels of cytokines and trophic factors.
In short, stem cell therapy could be one of the complementary treatments to alleviate sufferings in Covid-19 patients.
While stem cell therapy has been used in different health procedures for various ailments, the rise in the number of Covid-19 patients worldwide is an indication that the potential for companies that promote such treatment is certainly huge.
However, the stem cell banking industry in Malaysia has not been exploited yet as in-depth information about cord blood banking applications and clinical trials is still not widely available to the public.